BioDundee International Conference
Free Virtual Conference, Exhibition and Networking
Wednesday 12th May, 2021
09:00 – 16:30 (BST)
Click Here to download the Digital Conference Programme
The 20th BioDundee International Conference in association with AMICULUM and Medtronic took place virtually on Wednesday 12th May 2021, along with an accompanying exhibition and networking opportunity.
The theme of this year’s conference was “Life Sciences and Healthcare: Key Sectors for Economic Recovery” and featured speakers from academia, business and government across different sessions throughout the day.
Established in 1997, BioDundee is a partnership between the public, private and academic sectors. It aims to promote Dundee as a world-class centre for life science and healthcare activity, as well as build the strength of the sectors in the city and wider Tayside region.
Life Sciences and Healthcare: Key Sectors for Economic Recovery
Session 1 – The UK Landscape for Life Sciences and Healthcare: Funding and Legislation sponsored by MHA Henderson Loggie
Discussing the key trends within the life sciences sector (particularly drug discovery, digital health-tech, medical devices, artificial intelligence and the transition of healthcare from the hospital to the home) and the opportunities and impacts they represent for funding strategies. It will also cover recent legislative changes, along with pending legislation and the impact these may have for funding.
Featuring speakers from bio-tech companies, pharmaceutical companies and representatives from equity investment firms.
Session 2 – Driving Health Technologies in the New Environment sponsored by Scottish Health Innovations Limited (SHIL)
The growth in health innovation has already revolutionised patient care and the breakthroughs it brings will continue to go from strength to strength as part of a forward-thinking collaborative ecosystem. As a sector, life sciences are a vital contributor to Scotland and will deliver considerable growth in this period of change and opportunity.
HealthTech’s work in supporting the NHS to innovate, optimise and redesign healthcare pathways makes it one of the most strategically important sectors to Scotland’s life sciences industry.
As we aim to continue to gradually emerge from the pandemic, our focus must remain firmly on accelerating innovation in Scotland to solve real problems in the NHS and Social care, while constantly creating jobs and opportunities.
The session aims to highlight some of the drivers & uniqueness that Scotland has to offer this sector and we will hear from experts on how the infrastructure can support and attract innovation to our shores.
A follow on event ‘Health Technology: Scotland’s Opportunity‘ took place on Wednesday 19th May.
CLICK HERE to watch Health Technology Event
Session 3 – The Pharmaceutical Supply Chain
The innovative pharmaceutical industry in Scotland is made up of small, medium and large companies which serve the drug discovery supply chain and provide medicine and services to patients.
This session will focus on The Scottish Life Sciences Covid-19 Strategic Response Plan and will feature panellists from four parts of the supply chain.
They will discuss the next steps of implementing the response plan, including the improved use of data; collaboration between industry, the NHS and government; and the creation of a vaccines and advanced therapies strategy.
Session 4 – Animal Health, Agri-tech and Aquaculture (AAA): Strengths and Opportunities in Scotland
Animal health, Agri-tech and Aquaculture features as a priority focus area for the Life Sciences Scotland Strategic Response Plan.
This session will look at some of the biggest opportunities for growth, including animal health research and development investment to help contribute to tackling disease; the use of data and how it can drive innovation and emerging technologies; and the opportunity to tackle climate change through net zero projects within AAA.
Session 5 – 20 Years On: Reflecting and Looking to the Future sponsored by Research and Innovation Services, University of Dundee
Over the past 20 years there have been incredible discoveries and progress made by members of the BioDundee community, which have had a global impact and been recognised in international impact ratings.
Through Tay Cities and other projects, the research and related commercialisation base in the city is set to develop over the coming decades, with investment in infrastructure and resources, further establishing Dundee’s reputation as a hub for innovation and discovery.
This session will look back at some of these projects and their effect and look forward to what’s coming next.
Session 6 – What do the next 20 years hold for the Life Sciences and Healthcare Sectors? sponsored by Invest in Dundee
The session will focus on the ‘health is wealth’ agenda.
As the world seeks to recover from the effects of the global pandemic, it has been widely accepted that the existing models of health and care delivery are not sustainable into the future.
This creates real opportunities for collaboration between health and care delivery organisations, academia and industry to co-design with citizens the next generation of healthcare solutions.
The panel will share their views of the future direction of travel, where the emphasis should be to deliver maximum benefit and how Dundee (and Scotland) can play a leading role.
Itinerary
| 09:00: | Welcome and Introductions |
| 09:20: | Session 1 - The UK Landscape for Life Sciences and Healthcare: Funding and Legislation |
| 10:00: | Comfort Break - Networking and Exhibition |
| 10:20: | Session 2 - Driving Health Technologies in the New Environment |
| 11:00: | Comfort Break - Networking and Exhibition |
| 11:20: | Session 3 - The Pharmaceutical Supply Chain |
| 12:00: | Lunch - Networking and Exhibition |
| 13:00: | Session 4 - Animal Health, Agri-tech and Aquaculture (AAA): Strengths and Opportunities in Scotland |
| 13:40: | Comfort Break - Networking and Exhibition |
| 14:00: | Session 5 - 20 Years On: Reflecting and Looking to the Future |
| 14:40: | Comfort Break - Networking and Exhibition |
| 15:00: | Session 6 - What do the next 20 years hold for the Life Sciences and Healthcare Sectors? |
| 15:40: | Closing Address |
| 16:00: | Networking and Exhibition |
| 16:30: | Virtual Conference Closes |
Session 1
-
-
Sponsored by
MHA Henderson Loggie
-
Rod Mathers
Corporate Finance Partner, MHA Henderson Loggie (Chair)
-
Professor Andrew Hopkins
CEO, Exscientia
-
Dr Deborah O’Neil
Chief Executive Officer, NovaBiotics Ltd
-
Dr Samantha Atkinson
Interim Chief Quality & Access Officer, Medicines and Healthcare products Regulatory Agency (MHRA)
-
Dr Andrew McNeill
Managing Partner, Eos Advisory
Session 2
-
-
Sponsored by
Scottish Health Innovations Ltd (SHIL)
-
Peter Ellingworth
Chief Executive, ABHI (Chair)
-
Mark Cook
Director of Government Affairs, Medtronic
-
Jonathan Cameron
Deputy Director for Digital Health & Care, Scottish Government
-
Dr Debbie Wake
CEO and cofounder MyWay Digital Health, NHS Diabetes Consultant, Clinical Reader, University of Edinburgh
-
Professor Emily Jefferson
Director Health Informatics Centre (HIC), University of Dundee
Session 3
-
-
Dave Tudor
Managing Director MMIC, Biologics and Quality CPI (Chair)
-
Colin MacKay
CEO, Symbiosis Pharmaceutical Services
-
Tom Shepherd
Chief Executive Officer, Captor Therapeutics
-
Dr Julie Brady
Business Development Manager for Drug Discovery University of Dundee
-
John Arthur
Director, Medicines Manufacturing Innovation Centre, CPI
Session 4
-
-
John MacKenzie
CEO, Roslin Innovation Centre (Chair)
-
David Farquhar
CEO, IGS Limited
-
Dr. Jenna Bowen
Postdoctoral Researcher, SRUC / SEFARI Fellow
-
Dr Simon Doherty
GlobalScot, Institute of Global Food Security, Queen's University Belfast
-
Dr Lawrence Brown BVM&S MBA MRCVS
Innovation Manager for Health, Edinburgh Innovations
Session 5
-
-
Sponsored by
Research and Innovation Services, University of Dundee
-
Alison Henderson
Chief Executive Officer, Dundee and Angus Chamber of Commerce (Chair)
-
Robin Presswood
Executive Director of City Development, Dundee City Council
-
Mary Ballantyne
Independent Consultant / Current Team Leader, Covid-19 Immunisation Programme, NHS Tayside
-
Sir Mike Ferguson
Regius Professor of Life Sciences, University of Dundee
-
Professor Derek Stewart
Director of the Advanced Plant Growth Centre, The James Hutton Institute
-
Simon Hewitt
Principal, Dundee & Angus College
Session 6
-
-
Sponsored by
Invest in Dundee
-
George Crooks, OBE
Chief Executive Office, Digital Health & Care Innovation Centre (Chair)
-
Richard Hebdon
Interim Deputy Director – Health & Life Sciences, Innovate UK
-
Calum MacRae MD, PhD
Director, One Brave Idea / Vice Chair for Scientific Innovation, Department of Medicine, Brigham and Women's Hospital / Professor, Harvard Medical School
-
Dr. Alison Dun
Executive Director, Scottish Universities Life Sciences Alliance (SULSA)
-
Andrew Fowlie
Lead for Health, Social Care and Industrial Innovation and Scottish Health Industry Partnership, Chief Scientist Office, Directorate for Chief Medical Officer, The Scottish Government
Event Sponsors
AMICULUM® is an independent global health communications and consultancy business that works with pharmaceutical, biotechnology and health technology companies across the world. Our specialist services include medical communications, healthcare learning, creative design, clinical and commercial consultancy, support for market access and digital engagement. AMICULUM supports products in a wide range of therapy areas and has teams that focus specifically on rare diseases and advances in genomic medicine.
Created in 2001, AMICULUM has grown steadily for the past 20 years and now employs over 300 people worldwide. We have teams based across multiple locations in New Zealand, China, Hong Kong, Singapore, UAE, Switzerland, UK and USA. We have a team based on the campus of the University of Dundee.
Visit AMICULUM website
Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together. Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value — for healthcare systems, providers, and the people they serve.
Visit Medtronic website
AMICULUM® is an independent global health communications and consultancy business that works with pharmaceutical, biotechnology and health technology companies across the world. Our specialist services include medical communications, healthcare learning, creative design, clinical and commercial consultancy, support for market access and digital engagement. AMICULUM supports products in a wide range of therapy areas and has teams that focus specifically on rare diseases and advances in genomic medicine.
Created in 2001, AMICULUM has grown steadily for the past 20 years and now employs over 300 people worldwide. We have teams based across multiple locations in New Zealand, China, Hong Kong, Singapore, UAE, Switzerland, UK and USA. We have a team based on the campus of the University of Dundee.
Visit AMICULUM websiteMaking healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together. Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value — for healthcare systems, providers, and the people they serve.
Visit Medtronic websiteHenderson Loggie has been serving Scotland and Scottish business for well over a century. Our vision is to be first choice in Scotland as a place to work and for our services to our clients.
Our purpose is to help our teams and our clients achieve their potential, to create wealth for the local economy now and to leave legacy for the future in the communities where we are located.
We have a specialist Lifescience sector team and have been involved with Bio-Dundee since its inception, we are proud to be sponsors of this year’s event.
Visit MHA Henderson Loggie websiteInvest in Dundee is an inward investor service delivered by Dundee City Council in partnership with local and national agencies. It aims to promote Dundee as a world class location for investment and to provide potential investors with information and support. With a regenerated waterfront, an international class design museum in V&A Dundee, a spectacular river setting, 2 industry focused universities, a commitment to green recovery and an affordable cost base, there has never been a better time to consider Dundee.
Visit Invest in Dundee websiteScottish Health Innovations Ltd (SHIL) woks in partnership with NHS Scotland to identify, protect, develop and commercialise forward-thinking, impactful healthcare innovations that positively impact health, social and economic outcomes in Scotland.
Drawing on almost 20 years of operational experience, SHIL’s multidisciplinary team utilises specialised knowledge to help bring new ideas and innovations from healthcare professionals to life. Expert services including intellectual property advice and protection, regulatory expertise, project management, idea incubation, funding advice, development and commercialisation, and post-commercialisation monitoring.
SHIL believes ground breaking ideas have the power to significantly improve health and social care for all, while supporting an ambitious, entrepreneurial, forward-thinking Scotland. Working collaboratively with the NHS, academia, industry, entrepreneurs and funders we are committed to accelerating innovation and entrepreneurism across all areas of health.
Visit Scottish Health Innovations Ltd (SHIL) websiteSymbiosis is a world class manufacturer specialising in cGMP sterile fill/finish of biopharmaceuticals for clinical trials and niche commercial markets including viral vector Advanced Therapeutics Medicinal Products (ATMPs). The competitive strengths of Symbiosis include MHRA and FDA-inspected standard regulatory compliance, expert technical capabilities and exceptional operational flexibility.
Incorporated in 2011, Symbiosis has specialist capabilities to support biotechnology and pharmaceutical clients who are developing either biologic or small molecule injectable drug products. One of the company’s key strengths is in accelerating the release of drug product which provides significant value by ensuring clients tight timelines are successfully met.
Manufacturing takes place in a first-class manufacturing facility, enabling Symbiosis to manufacture a broad range of liquid or lyophilized drug products including viral vectors, antibodies, proteins, peptides and small molecules in addition to the ability to handle cytotoxic anti-cancer drugs and antibody-drug conjugates.
Visit Symbiosis Pharmaceutical Services websiteThe School of Life Sciences at the University of Dundee offers several technologies and resources to support state-of-the-art biomedical and biological sciences research. The facilities in our Centre for Advanced Scientific Technologies and our Data Analysis Group are also integral to our interdisciplinary and collaborative research ethos.
2021 Exhibitors
AMICULUM® is an independent global health communications and consultancy business that works with pharmaceutical, biotechnology and health technology companies across the world. Our specialist services include medical communications, healthcare learning, creative design, clinical and commercial consultancy, support for market access and digital engagement. AMICULUM supports products in a wide range of therapy areas and has teams that focus specifically on rare diseases and advances in genomic medicine.
Created in 2001, AMICULUM has grown steadily for the past 20 years and now employs over 300 people worldwide. We have teams based across multiple locations in New Zealand, China, Hong Kong, Singapore, UAE, Switzerland, UK and USA. We have a team based on the campus of the University of Dundee.
Visit AMICULUM websiteMaking healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together. Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value — for healthcare systems, providers, and the people they serve.
Visit Medtronic websiteHenderson Loggie has been serving Scotland and Scottish business for well over a century. Our vision is to be first choice in Scotland as a place to work and for our services to our clients.
Our purpose is to help our teams and our clients achieve their potential, to create wealth for the local economy now and to leave legacy for the future in the communities where we are located.
We have a specialist Lifescience sector team and have been involved with Bio-Dundee since its inception, we are proud to be sponsors of this year’s event.
Visit MHA Henderson Loggie websiteInvest in Dundee is an inward investor service delivered by Dundee City Council in partnership with local and national agencies. It aims to promote Dundee as a world class location for investment and to provide potential investors with information and support. With a regenerated waterfront, an international class design museum in V&A Dundee, a spectacular river setting, 2 industry focused universities, a commitment to green recovery and an affordable cost base, there has never been a better time to consider Dundee.
Visit Invest in Dundee websiteScottish Health Innovations Ltd (SHIL) woks in partnership with NHS Scotland to identify, protect, develop and commercialise forward-thinking, impactful healthcare innovations that positively impact health, social and economic outcomes in Scotland.
Drawing on almost 20 years of operational experience, SHIL’s multidisciplinary team utilises specialised knowledge to help bring new ideas and innovations from healthcare professionals to life. Expert services including intellectual property advice and protection, regulatory expertise, project management, idea incubation, funding advice, development and commercialisation, and post-commercialisation monitoring.
SHIL believes ground breaking ideas have the power to significantly improve health and social care for all, while supporting an ambitious, entrepreneurial, forward-thinking Scotland. Working collaboratively with the NHS, academia, industry, entrepreneurs and funders we are committed to accelerating innovation and entrepreneurism across all areas of health.
Visit Scottish Health Innovations Ltd (SHIL) websiteSymbiosis is a world class manufacturer specialising in cGMP sterile fill/finish of biopharmaceuticals for clinical trials and niche commercial markets including viral vector Advanced Therapeutics Medicinal Products (ATMPs). The competitive strengths of Symbiosis include MHRA and FDA-inspected standard regulatory compliance, expert technical capabilities and exceptional operational flexibility.
Incorporated in 2011, Symbiosis has specialist capabilities to support biotechnology and pharmaceutical clients who are developing either biologic or small molecule injectable drug products. One of the company’s key strengths is in accelerating the release of drug product which provides significant value by ensuring clients tight timelines are successfully met.
Manufacturing takes place in a first-class manufacturing facility, enabling Symbiosis to manufacture a broad range of liquid or lyophilized drug products including viral vectors, antibodies, proteins, peptides and small molecules in addition to the ability to handle cytotoxic anti-cancer drugs and antibody-drug conjugates.
Visit Symbiosis Pharmaceutical Services website
Johnston Carmichael is the largest firm of Chartered Accountants and Business Advisers in Scotland with 13 offices, including Dundee, and over 750 staff and partners. We have a global reach via our membership of PKF International, a network of independent member firms with over 400 offices in 150 countries.
Our team of sharp minds use their expertise and experience to act as trusted advisers offering detailed knowledge of your sector and keen insight to meet your individual needs across audit, tax, personal finance and other key areas.
Visit Johnston Carmichael website
Cellexus research, develop and manufacture the CellMaker range of revolutionary single-use, airlift bioreactor systems and related technology.
The most innovative airlift technology on the market, the CellMaker system offers a reduced investment alternative to existing technologies with a combined low footprint and excellent performance. The CellMaker bioreactors are available in 8L and 50L and the option of fitted sensors for pH and dissolved oxygen to enhance process control, maximise yields and reduce time to market. The CellMaker range is designed to be versatile and has been proven in a wide range of cell lines (E Coli, Pichia, Bacteriophage, Yeast, Algae) for fermentation applications used in the life sciences and biopharmaceutical industries. We enable our customers to accelerate their processes and increase their yields when compared to standard methods.
Visit Cellexus website